• In the past week, Edwards Lifesciences reported Q4 2025 sales of US$1,569.6 million and full-year 2025 sales of US$6.07 billion, alongside issuing 2026 guidance calling for first-quarter sales of US$1.55 billion to US$1.63 billion and full-year EPS of US$2.90 to US$3.05.
• While revenue continued to grow, the sharp drop in quarterly and full-year net income and EPS highlights how margin pressure and one-off factors are shaping Edwards’ profit profile as it invests behind its Structural Heart portfolio.
• We’ll now examine how Edwards’ 2026 EPS guidance of US$2.90 to US$3.05 reshapes its existing investment narrative and risk balance.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Edwards Lifesciences Investment Narrative Recap

To own Edwards Lifesciences, you need to believe in long term adoption of its Structural Heart therapies translating into durable revenue and EPS growth. The new 2026 EPS guidance of US$2.90 to US$3.05 helps frame the key near term catalyst as execution on that earnings target, while the sharp drop in 2025 net income keeps margin pressure and cost intensity as the most immediate risk. For now, the guidance itself does not materially alter that balance.

The most relevant recent update here is Edwards’ full year 2026 outlook, which calls for 8% to 10% sales growth alongside that US$2.90 to US$3.05 EPS range. Against the backdrop of softer 2025 profitability, this guidance effectively ties the near term story to whether new products such as SAPIEN M3 and broader TAVR adoption can support both top line expansion and a recovery in earnings power without pushing operating expenses or tariffs related costs too far.

Yet investors should also be aware that rising operating expenses and tariff headwinds could pressure those EPS targets if revenue momentum slows...

Edwards Lifesciences' narrative projects $7.6 billion revenue and $1.8 billion earnings by 2028. This requires 10.0% yearly revenue growth and roughly a $0.4 billion earnings increase from $1.4 billion today.

Uncover how Edwards Lifesciences' forecasts yield a $97.11 fair value, a 26% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community currently see fair value for Edwards between US$70.82 and US$97.11, highlighting a wide band of expectations. Set against the company’s 2026 EPS guidance of US$2.90 to US$3.05, this spread underlines how differently investors weigh tariff risks and margin pressure on future performance.

Explore 3 other fair value estimates on Edwards Lifesciences - why the stock might be worth as much as 26% more than the current price!

Build Your Own Edwards Lifesciences Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Edwards Lifesciences research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Edwards Lifesciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Edwards Lifesciences' overall financial health at a glance.

Curious About Other Options?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with 27 elite penny stocks that balance risk and reward.
• We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Outshine the giants: these 26 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.